Michael D Tarantino

11PUBLICATIONS
48CO-AUTHORS
Haematological tumoursHaematologyGene and molecular therapyAnimal protection (incl. pests and pathogens)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 23, 2025
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.

Nichola Cooper, A J Gerard Jansen, Robert Bird

|Nov 28, 2023
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD.

Jonathan C Roberts, Pamela A Christopherson, Michael D Tarantino

|Aug 17, 2023
Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.

Craig M Kessler, Fernando F Corrales-Medina, Pier Mannuccio Mannucci

|Aug 16, 2023
Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.

Michael D Tarantino, Brandon Hardesty, Ara Metjian

|Jun 20, 2023
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.

Michael D Tarantino, James B Bussel, Eun-Ju Lee

|Jun 06, 2023
Plasma gastric biomarker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials.

James B Bussel, Michael D Tarantino, Eun-Ju Lee

Pageof 2

Frequent Collaborators

4 joint publications

Jonathan C Roberts

2 joint publications

Eun-Ju Lee

2 joint publications

James B Bussel

1 joint publications

David J Kuter